Your browser doesn't support javascript.
The association between statin and COVID-19 adverse outcomes: national COVID-19 cohort in South Korea.
Chow, Ronald; Lee, Jihui; Noh, Hyerim; Lee, Jongseong; Simone, Charles B; Shin, Hyun Joon; Choi, Young-Geun.
  • Chow R; Hanyang Impact Science Research Center, Seoul, South Korea; New York Proton Center, New York, NY, USA; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Lee J; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
  • Noh H; Department of Statistics, Sookmyung Women's University, Seoul, South Korea.
  • Lee J; School of Social Work, Columbia University, New York, NY, USA; Ministry of Health and Welfare, Sejong, South Korea.
  • Simone CB; New York Proton Center, New York, NY, USA.
  • Shin HJ; Hanyang Impact Science Research Center, Seoul, South Korea; Division of Cardiology, Department of Medicine, Lemuel Shattuck Hospital, Massachusetts Department of Public Health, Jamaica Plains, MA, USA; Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Bosto
  • Choi YG; Department of Statistics, Sookmyung Women's University, Seoul, South Korea; Research Institute of Natural Science, Sookmyung Women's University, Seoul, South Korea.
Ann Palliat Med ; 11(4): 1297-1307, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1786442
ABSTRACT

BACKGROUND:

There currently exist limited and conflicting clinical data on the use of statins in coronavirus disease 2019 (COVID-19) patients. The aim of this paper was to compare hospitalized patients with COVID-19 who did and did not receive statins.

METHODS:

We performed a population-based retrospective cohort study using South Korea's nationwide healthcare claim database. We identified consecutive patients hospitalized with COVID-19 and aged 40 years or older. Statin users were individuals with inpatient and outpatient prescription records of statins in the 240 days before cohort entry to capture patients who are chronic statin users and, therefore, receive statin prescriptions as infrequently as every 8 months. Our primary endpoint was a composite of all-cause death, intensive care unit (ICU) admission, mechanical ventilation use and cardiovascular outcomes [myocardial infarction (MI), transient cerebral ischemic attacks (TIA) or stroke]. We compared the risk of outcomes between statin users and non-users using logistic regression models after inverse probability of treatment weighting (IPTW) adjustment.

RESULTS:

Of 234,427 subjects in the database, 4,349 patients were hospitalized with COVID-19 and aged 40+ years. In total, 1,115 patients were statin users (mean age =65.9 years; 60% female), and 3,234 were non-users (mean age =58.3 years; 64% female). Pre-hospitalization statin use was not significantly associated with increased risk of the primary endpoint [IPTW odds ratio (OR) 0.82; 95% confidence interval (CI) 0.60-1.11]. Subgroup analysis showed a protective role of antecedent statin use for individuals with hypertension (IPTW OR 0.40; 95% CI 0.23-0.69, P for interaction 0.0087).

CONCLUSIONS:

Pre-hospitalization statin use is not detrimental and may be beneficial amongst hypertensive COVID-19 patients. Further investigation into statin is needed for more conclusive effects of statins for treatment of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Ann Palliat Med Year: 2022 Document Type: Article Affiliation country: Apm-21-3464

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Ann Palliat Med Year: 2022 Document Type: Article Affiliation country: Apm-21-3464